Clinical Trial Update: HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reporting completion of a phase 1/2 study of the HDAC inhibitor vorinostat in resistant BRAF V600-mutated advanced melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Neoplasms of Skin

Drugs mentioned

• Vorinostat (Zolinza) (vorinostat)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Melanoma, Skin Neoplasms | Phase 1, Phase 2 | Status: COMPLETED